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Abstract  
X-linked Sideroblastic Anemia (XLSA) is the most common genetic form of sideroblastic 
anemia, a heterogeneous group of disorders characterized by iron deposits in the mitochondria 
of erythroid precursors. XLSA is due to mutations in the erythroid-specific 5-aminolevulinate 
synthase (ALAS2) gene. Thirteen different ALAS2 mutations were identified in 16 out of 29 
probands with sideroblastic anemia. One third of the patients were females with a highly 
skewed X-chromosome inactivation. The identification of seven novel mutations in the 
ALAS2 gene, six missense mutations, and one deletion in the proximal promoter extends the 
allelic heterogeneity of XSLA. Most of the missense mutations were predicted to be 
deleterious and ten of them, without any published functional characterization, were 
expressed in E. coli. ALAS2 activities were assayed in vitro. Five missense mutations resulted 
in decreased enzymatic activity under standard conditions, and two other mutated proteins 
had  decreased activity when assayed in the absence of exogenous pyridoxal phosphate and 
increased thermosensitivity. Although most amino-acid substitutions result in a clearly 
decreased enzymatic activity in vitro, a few mutations have a more subtle effect on the protein 
that is only revealed by in vitro tests under specific conditions. 
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X-linked Sideroblastic Anemia, ALAS2, heme synthesis, protoporphyrin 
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Introduction 
 
Congenital sideroblastic anemia (CSA) comprises a group of heterogeneous disorders 
characterized by decreased heme synthesis and mitochondrial iron overload with ringed 
sideroblasts in the bone marrow (For a review, see Camaschella, 2009). The most common 
genetic form of CSA, X-linked Sideroblastic Anemia (XLSA, MIM# 300751), results from 
mutations in the specific erythroid gene encoding 5-aminolevulinate synthase (ALAS2, also 
known as ALASE, MIM *301300, EC 2.3.1.37) (Fleming, 2002) localized on chromosome 
Xp11.21. ALAS is the first enzyme in the heme biosynthesis pathway and catalyzes the 
condensation of glycine and succinyl-coenzyme A into 5-aminolevulinic acid (ALA), the 
precursor of the tetrapyrroles (Gibson, et al., 1958; Shemin and Kikuchi, 1958). Pyridoxal 5’-
phosphate (PLP) is the cofactor of the enzyme. Most of the 48 reported ALAS2 mutations 
responsible for XLSA are missense mutations localized in exons 4 to 11 (Bergmann, et al.). A 
variant in the proximal promoter was first reported as a mutation in an XLSA patient (Bekri, 
et al., 2003), but this variant was subsequently found in unaffected individuals, leading to the 
conclusion that it is a low frequency polymorphism and not a causal mutation (May A., 2005) 
Most of these mutations were described at the genomic lev l without further characterization 
of the mutated protein either in vitro or in vivo. In some patients, reduced ALAS enzymatic 
activity has been reported in the bone marrow (Bottomley, et al., 1992; Cotter, et al., 1995; 
Cox, et al., 1994; Harigae, et al., 1999a), and in others the mutated cDNA has been expressed 
in E. coli in order to study the activity of mutated protein (Cotter, et al., 1992; Cotter, et al., 
1995; Cotter, et al., 1994; Cox, et al., 1994; Furuyama, et al., 1997; Furuyama, et al., 2006; 
Furuyama, et al., 1998; Harigae, et al., 1999a; Harigae, et al., 1999b; Prades, et al., 1995). In 
addition, in 2005, the crystallographic structure of ALAS2 from Rhodobacter capsulatus (R. 
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capsulatus) was published, making it possible to map the XLSA causing mutations (Astner, et 
al., 2005). 
Here we report a series of 29 probands with SA. Thirteen different ALAS2 mutations were 
found in 16 probands. Seven of the 13 mutations had never previously been described, 
including a 48-bp deletion in the proximal promoter region. The functional impact of the 12 
remaining missense mutations was assessed in silico using bioinformatic tools. Moreover, 
cDNAs were expressed in E. coli in order to assess the functional consequences of ten amino-
acid substitutions for six novel mutations and four previously reported but so far 
uncharacterized mutations. ALAS2 activity, enzyme thermosensitivity and pyridoxine 
responsiveness were studied. 
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Materials and Methods 
Patients 
We performed genetic analyses in 29 probands (17 males and 12 females) referred to our 
laboratory with a diagnosis of CSA based on the presence of sideroblasts in the bone marrow. 
Patients with syndromic or acquired forms of SA were excluded from this study. These 
patients originated from France, other Western European countries (Germany, Switzerland, 
Belgium) and Tunisia. Blood samples for genetic analysis were obtained from the patients or 
their parents after they had given signed informed consent in accordance with the 
requirements of the French Bioethics Committee “Agence of Biomedecine”. Hematological 
parameters had been evaluated by standard methods in the respective referring hospitals, and 
erythrocyte protoporphyrin was measured as previously described (Deacon and Elder, 2001).  
 
X-inactivation study 
Analysis of X chromosome inactivation was performed as previously described (Chollet-
Martin et al., 2007) using the androgen receptor polymorphism as a marker. 
 
Molecular analysis of the ALAS2 gene  
Genomic DNA was extracted from peripheral blood using the QIAamp DNA blood Mini Kit 
(Qiagen, CA, USA). Analysis of the ALAS2 gene (Genbank genomic: NG_008983.1, 
Genbank mRNA: NM_000032.4, Genbank protein: NP_000023.2) was performed by 
bidirectional direct sequencing. The 11 exons of ALAS2, the proximal promoter (250 bp) and 
the exon-intron junctions were amplified by PCR (Supp. Table S1). After purification of PCR 
products (PCR purification kit, Qiagen CA, USA), both strands were sequenced using a Big 
Dye Terminator Cycle Sequencing kit (Applied Biosystems, Life Technologies, Carlsbad, 
CA, USA). Sequencing products were purified (Sephadex G50, GE Healthcare, Piscataway, 
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NJ, USA), and analyzed using a 3130xl Genetic Analyzer (Applied Biosystems, Life 
Technologies, Carlsbad, CA, USA) and the Seqscape analysis software (v2.6.0) (Applied 
Biosystems, Life Technologies, Carlsbad, CA, USA). Identified mutations were confirmed on 
a second sample, when available, or by family study. Numbering of ALAS2 mutations 
followed the international guidelines (www.hgvs.org/mutnomen). For the nucleotide 
numbering, +1 corresponds to the A of the ATG translation initiation codon in the reference 
sequence of the cDNA; for the amino acid numbering position 1 corresponds to the initiating 
methionine.  
 
In silico prediction of the functional impact of ALAS2 mutations 
The Grantham score (Grantham, 1974) and six bioinformatic tools were used in silico to 
predict the impact of ALAS2 mutations on protein structure or function, as previously 
described (Kannengiesser, et al., 2009). The bioinformatic tools consisted of polyphen 
(Sunyaev, et al., 2001), SIFT (Ng and Henikoff, 2003), SNP3D (Yue, et al., 2006), 
PANTHER (Brunham, et al., 2005), UMD Predictor (Frederic, et al., 2009) and GVGD 
(Tavtigian, et al., 2006).  
To get an overall estimate of the impact of each mutation, we calculated a “prediction score” 
from the number of programs that predicted that the alteration would be deleterious 
(Grantham score >100; GVGD: C25-C65; PANTHER: highly/probably deleterious; SIFT: 
affected; polyphen: damaging; UMD predictor: pathogenic; SNP3D: deleterious). 
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Localization of amino acids in Rhodobacter capsulatus 
The localization of the mutated amino acids in the 3D structure of ALAS2 was predicted by 
sequence homology using the crystal structure of ALAS from R. capsulatus (PDB 2BWN, 
2BWO and 2BWP) and Rasmol software (Sayle and Milner-White, 1995).   
 
Expression of normal and mutant ALAS2 enzymes in E. coli 
To investigate the effect of the mutations on ALAS2 activity, mutant enzymes were expressed 
in E. coli starting from a construct with the normal cDNA (pMALc2-AE2) kindly provided by 
Dr David Bishop (Cotter, et al., 1994). pMALc2-AE2 encodes a recombinant fusion protein 
consisting of a maltose binding protein (MBP, 387 AA) linked to the N-terminus of the 
mature human ALAS2 (509AA).  We introduced the different mutations by site-directed 
mutagenesis using a Quick change kit (Stratagene, La Jolla, CA, USA) according to the 
manufacturer’s instructions. The sequences of the mutagenesis primers are available upon 
request. The coding region of the resulting cDNAs was verified by sequencing.  
Escherichia coli BL21 DE3 competent cells (Invitrogen, Life Technologies, Carlsbad, 
California, USA) were transformed with expression plasmids, and overnight cultures were 
grown in LB (Lennox L Broth Base, Invitrogen, Life Technologies, Carlsbad, California, 
USA) medium with 100 mg/ml ampicillin (PANPHARMA, Fougères - France). The next day, 
20 ml of cultures in LB/ampicillin medium were initiated with the overnight cultures and 
grown to 1.2 A600 units. ALAS2 synthesis was induced by adding 0.1 mM isopropyl b-D-
thiogalactopyranoside (IPTG) in the presence of 0.5 mM 4,6-dioxoheptanoic acid (Sigma-
Aldrich, St. Louis, MO, USA), also known as succinyl acetone, a strong inhibitor of the ALA 
dehydratase enzyme to prevent the transformation of ALA into porphyrins. Incubation was 
carried out in LB/ampicillin medium for 4 hr at 22°C. Cells were pelleted at 2500 rpm for 10 
min, and then frozen at -80°C. The assay of ALAS2 activities of the control and mutant 
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enzymes under standard conditions was performed on crude bacterial lysates as previously 
described (Lien and Beattie, 1982) with modifications. Pellets were sonicated in 300 µl of 
HEPES 50 mM pH 7.5 while maintained in ice. The total protein concentration was measured 
by means of a protein assay (Bio-Rad Laboratories GmBh, Hercules, CA, USA), and the 
samples were adjusted to a concentration of 0.2 mg of total protein/ml. Six hundred µl of 
samples were preincubated for 5 minutes at 37°C before the assay, then 100 µl of a mixture 
containing 1 mM Succinyl-CoA, 10 mM Glycine, 50 mM HEPES and 0.5 mM PLP (all from 
Sigma-Aldrich, St. Louis, MO, USA) were added to samples. The reaction was stopped by 
adding 60 µl of 100% trichloroacetic acid either immediately (T0) or after 20 minutes (T20) 
at 37°C. The reaction product 5-aminolevulinate (ALA) was quantified by colorimetry, after a 
reaction of ALA with acetyl acetone (Fluka analytical, Sigma-Aldrich, St. Louis, MO, USA) 
(Mauzerall and Granick, 1956). The ALA pyrroles were not separated from other pyrroles 
present in the bacterial lysate before adding Erlich’s reagent. Instead, the ALA synthesized 
during the incubation was calculated from the OD obtained with Erlich’s reaction after 
subtracting a blank corresponding to the OD obtained with the lysate from a bacterial clone 
expressing the ALAS2 C344X mutant. This mutant encodes a truncated protein shown to be 
devoid of enzymatic activity by the lack of difference in OD between T0 and T20 (data not 
shown). We checked that all bacterial lysates corresponding to wild type and mutant 
recombinant ALAS2 (including the C344X mutant) yielded identical OD values at T0. 
The specific activity (SA) was expressed in pmol of ALA/mg total protein at 37°C. The 
residual activity (%) was determined by expressing the specific activity of mutants relative to 
that of the wild type ALAS2.  
In some cases, specific assay conditions were used consisting of either omitting PLP from the 
incubation mixture or preincubating the bacterial lysate at 37°C for 30 or 60 minutes instead 
of 5 minutes.  The significance of the results was estimated using Student’s t-test.   
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Immunoblotting 
2.5 µg of total protein of the supernatant from bacteria lysates were taken up onto 1X 
Laëmmli buffer, and heated for 10 minutes at 100°C. Samples were analysed by SDS-PAGE 
using an 8% polyacrylamide gel followed by electro-transfer on a polyvinylidene fluoride 
(PVDF) membrane. Loading and transfer were confirmed by Ponceau red staining. After pre-
incubation in blocking solution (7% skimmed milk in Tween 20 in Tris buffered saline, TBST 
0,15%) overnight at 4°C, the membrane was incubated with an anti-MBP antiserum (1/20 
000, E8030S, New England Biolabs, Ozyme, Ipswich, MA, USA) for 2H at room 
temperature. After washing three times with TBST for 10 minutes each time, the membrane 
was incubated with a secondary anti rabbit IgG, linked to Horseradish peroxidase (1/20 000, 
Amersham GE Healthcare, Piscataway, NJ, USA) for 2H at room temperature. The MBP 
fusion proteins were visualized (Immobilon Western, chemiluminescent HRP substrate, 
Millipore Corporation, Billerica, MA, USA) according to the Manufacturer’s instructions.  
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Results 
Twenty-nine patients with a diagnosis of CSA were referred to our laboratory for molecular 
exploration. All of them had ringed sideroblasts in the bone marrow, and most of them had 
mild to severe anemia at the time of referral. The ALAS2 gene was sequenced. Thirteen 
different mutations, including 12 substitutions and 1 deletion, were identified in 16 probands 
(10 males and 6 females). Table 1 summarizes clinical data for patients carrying an ALAS2 
mutation.  
Five of the six affected females had highly skewed X inactivation consistent with a diagnosis 
of XLSA (data not shown). The remaining affected female (proband 8) was not informative 
for the androgen receptor polymorphism.  
Six of these mutations had already been reported (Bottomley, 2004; Bottomley, et al., 1995; 
Goncalves, et al., 2004; May and Bishop, 1998), whereas the other seven had not been 
described before (Harigae and Furuyama). Twelve of these 13 mutations caused amino acid 
substitutions (Table 1), and the thirteenth was a 48-bp deletion (c.-91_-44del) in the proximal 
promoter (Table 1 and Figure 1). This deletion led to the removal of the TATA-like box 
localized between -82 and -76 bp upstream of the translational initiating codon (Cox, et al., 
1991) and of the first 9 nucleotides of exon 1. A rare P520L variant, previously reported as a 
putative modifier of iron overload with an allelic frequency of 0.0013 in Caucasians (Lee, et 
al., 2006), was found in one female proband (number 13, Table 1) in the absence of any other 
sequence variation.  
Erythrocyte protoporphyrin concentration was measured in six patients carrying an ALAS2 
mutation (Table 1). In all XLSA cases, the protoporphyrin concentration was within the 
normal range of values (less than 1.9 µmoles/L of red blood cells).  
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We used various different in silico software products to predict the functional consequences 
of the ALAS2 missense mutations. All the substitutions were predicted to be deleterious, apart 
from R218H and E242K (Supp. Table S2).  
To assess in vitro the functional consequences of ten amino acid substitutions that had not 
been studied before (ten missense mutations corresponding to six novel mutations and four 
previously reported mutations without functional data) we expressed the mutant cDNAs in 
E. coli. Immunoblotting was performed to confirm that the expression level of recombinant 
normal and mutant proteins were similar (Supp. Figure S1). When the enzymatic activity was 
assayed from E. coli lysates immediately after cell disruption, five ALAS2 mutants (E242K, 
D263N, P339L, R375C, R411H) displayed significantly reduced ALAS2 activity, with 
residual activity ranging between 14 and 65 % of the normal construct (Figure 2 and Table 2).  
Expression of the remaining five mutated cDNAs (R170H, R218H, R452G, P520L and 
R572H) resulted in the production of a protein with an enzymatic activity that was no 
different from that of the normal construct.  
For four mutants, we also measured the activity of the protein in the absence of added 
exogenous PLP (Figure 3a). R170H and R218H mutants displayed significantly reduced 
activity in this situation, whereas neither R452H nor R572H did. We also tested the thermal 
stability of these four mutated enzymes by pre-incubating them at 37°C for 30 or 60 minutes 
prior to the enzymatic assay (Figure 3b). Once again, the R170H and R218H mutants 
displayed significantly increased thermosensitivity, while the R452H and R572H mutants did 
not significantly differ from the wild type. Adding exogenous PLP to the preincubation 
medium prevented the loss of activity induced by preincubating at 37°C for all the mutants as 
well as for the normal enzyme (data not shown). 
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Discussion 
The results reported here for a series of 29 probands with CSA highlights a number of 
interesting points regarding the genetic heterogeneity of the disease and the functional 
consequences of ALAS2 mutations. ALAS2 variants were found in 16 out of the 29 probands, 
including a P520L variant previously reported as being a rare polymorphism (Lee, et al., 
2006). Recently, other gene defects have been identified in autosomal recessive forms of CSA 
(MIM #205950): a homozygous mutation was found in GLRX5 in a consanguineous proband 
(Camaschella, et al., 2007), and SLC25A38 which encodes a putative glycine transporter, was 
found to be mutated in the affected members of different families (Guernsey, et al., 2009). 
Thus for the 13 probands without any ALAS2 mutation, and for one patient with the P520L 
variant, these two genes were explored and mutations were identified in SLC25A38 for four 
probands (manuscript submitted). No variant was identified in any of the three genes explored 
in the other 9 patients; the characteristics available for these patients are reported in Suppl. 
table S3). This proportion is similar to that reported by Bergmann et al. (Bergmann, et al., 
2010), suggesting that other loci must be involved. 
Our data extend the allelic heterogeneity of XSLA, since we identified seven novel mutations 
including a deletion in the proximal promoter region, in addition to five mutations already 
known. As expected, XLSA symptomatic heterozygous females displayed highly skewed 
X-chromosome inactivation (Aivado, et al., 2006; Cazzola, et al., 2000).  
We clearly show that a defect in the first step of the heme biosynthetic pathway prevents the 
abnormal accumulation of erythrocyte protoporphyrin both in patients with ALAS2 mutations 
(Table 1) as well as in one patient with the SLC25A38 mutation (data not shown). Therefore, 
this simple measurement may provide a useful screening test before sequencing ALAS2 and 
SLC25A38. Indeed, elevated erythrocyte protoporphyrin levels have been described in other 
anemic syndromes, including many types of CSA linked to ABCB7, SLC19A2 or 
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mitochondrial defects (Camaschella, 2009). Furthermore, erythrocyte samples were available 
for three unexplained cases of CSA (without any identified mutations of ALAS2 or 
SLC25A38) out of the 14 in our series. In contrast to the XLSA patients, they had an elevated 
level of erythrocyte protoporphyrin (>1.9 µmoles/L red blood cells, data not shown).  
Finally, we addressed the functional consequences of ALAS2 mutations in order to evaluate 
their deleterious impact. The deletion in the proximal promoter of the ALAS2 gene led to the 
elimination of the TATA-like motif and the first 9 bp of exon 1. The TATA-like motif has 
been shown to be functionally important by mutagenesis studies (Surinya, et al., 1997). It is 
likely that some other sequence upstream of the deletion may act as a weak promoter, since 
ALAS2 mRNA was detected at a lower concentration in the bone marrow of the male patient 
15 than in unrelated controls (data not shown). The complete loss of ALAS2 expression is 
probably lethal, as shown by the absence of ALAS2-null embryos following specific 
disruption of ALAS2 gene in mice (Nakajima, et al., 1999).  
The finding of a previously reported variant P520L as the only sequence variation in a 
proband female with a highly skewed pattern of X-inactivation raises the question of the 
possible relevance of this mutation. However, expression studies of the P520L cDNA failed 
to reveal any functional impact. 
The functional consequence of the six novel missense mutations was evaluated by studying 
the enzymatic activity of the recombinant mutant protein expressed in E. coli. Three 
previously reported mutants, for which such data were not available, were also studied 
(Table 1). A significant decrease in the enzymatic activity measured in vitro was evidenced 
for five mutants: E242K, D263N, P339L, R375C and R411H (Table 3). The histidine 
substitution at position 411 (R411H mutation) decreased ALAS2 activity to the same extent 
as the cysteine substitution previously reported (Furuyama, et al., 1998).  
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For four other mutations (R170H, R218H, R452H, R572H), in vitro activity was not different 
from the wild type control under standard conditions. Two of these mutants (R170H and 
R218H) showed reduced activity in the absence of exogenous PLP and increased 
thermosensitivity.  This may be explained by reduced affinity for PLP and higher sensitivity 
to thermal denaturing of the apoenzyme as compared to the holoenzyme, the proportion of the 
two forms being modified by the presence of added PLP. These results are consistent with the 
structural analysis of ALAS from R. capsulatus leading to the prediction that the substitution 
of the R170 would affect the binding of PLP (Astner, et al., 2005). However, the patient with 
the R170H mutation did not respond to PLP therapy. Because in silico tools did not predict 
any deleterious impact for R218H, and because both this mutant and the R170H mutant 
behaved similarly in our functional studies, we localized the corresponding positions on the 
quaternary structure of R. capsulatus (see Supp. Figure S2). Interestingly, A75 (at a position 
homologous to that of R218 in humans) in one monomer is quite close to R28 (at homologous 
position to human R170) on the other monomer, suggesting the possibility that these two 
amino acids may be important for the dimerization of ALAS2. 
Finally, two mutated proteins, R452G and R572H, did not differ from the wild type in the in 
vitro system despite damaging in silico predictions. These two mutants were as active and as 
thermostable as the normal enzyme. Similar findings had previously been reported for other 
mutations, including R452C and R452H (Furuyama, et al., 2006). Although the R452G and 
R572H mutants did not display loss-of-function in E. coli, several lines of evidence support 
their implication in XLSA. The CGC codon encoding R452 is a hot spot for mutations. This  
arginine R452 has been found to be substituted in approximately one-quarter of patients with 
XLSA (Furuyama, et al., 2006). In our series, R452C occurred in two independent probands. 
Two independent probands were also carrier of the R572H mutation and one of them, for 
whom blood sample was available, showed an erythrocyte protoporphyrin concentration at the 
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lower end of the normal range. These observations suggest that R452G and R572H are causal 
mutations. We can hypothesize the implication of additional factors in the bone marrow or a 
defective enzyme processing as has been suggested for K299Q and D190V, previously 
reported to display normal activities (Cotter, et al., 1995; Furuyama, et al., 1997). 
As previously reported, iron overload may be a major complication of XLSA, and the iron 
depletion by either iron chelators or phlebotomy (Camaschella, 2008) not only effectively 
prevents the deleterious effects of iron overload, but also improves erythropoiesis.   
A correlation between these “milder” defects and the phenotype of the patients remains 
speculative, given the known intrafamilial variability of XSLA. It is noteworthy that the 
patient with R452G has a mild anemia, and the two patients with the R572H mutations have 
near-to-normal hemoglobin levels, microcytosis and a relatively late onset of the disease. It is 
interesting to note the wide variability in the degree of anemia in patients with ALAS2 
mutations, ranging from a baby boy with a very severe form of the disease requiring repeated 
blood transfusions (patient 3, see Table1), to patients with mild microcytosis diagnosed at age 
46 and 57 respectively (patients 14 and 15, see Table1). In these last two cases, the diagnosis 
was suspected because of iron overload in absence of transfusion, and confirmed by bone 
marrow examination revealing the presence of ringed sideroblasts.  
In conclusion, we confirm in a large cohort of patients that about half of the cases of non 
syndromic sideroblastic anemia are accounted for by ALAS2 mutations, and that a high degree 
of clinical heterogeneity parallels the diversity of the mutations and of their functional 
consequences.  
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Figure Legends 
 
Figure 1: Hemizygous deletion of 48 base pairs in the proximal promoter of ALAS2 gene 
A: PCR amplification of the promoter region from a normal control (lane 1; expected size 
627 bp); male proband 15 (lane 2; shorter PCR product of 579 bp) and his mother (lane 3; 
healthy carrier); M: DNA molecular weight markers (Fermentas, 100 bp ladder); 
B: Sequence of the proximal promoter of the ALAS2 gene (Adapted from Cox, et al., 1991) 
showing the TATA-like box (in bold), the beginning of exon 1 (underlined), and the deletion 
(underlined in gray) 
 
Figure 2: Residual activities of the various different recombinant ALAS2 mutant 
enzymes assayed under standard conditions 
The residual activity of each mutant is expressed as a percentage of the normal enzyme 
activity as described in Material and Methods. Enzyme activity was measured on at least 3 
independent bacterial cultures. The statistical significance of comparisons of the specific 
activities between each mutant and the normal enzyme was established using Student’s t-test 
(*: p value < 0.05). Five mutants (E242K, D263N P339L, R375C and R411H) display 
significant loss-of-function. 
 
Figure 3: PLP-dependence and thermosensitivity of the recombinant normal and 
mutant ALAS2  
A/ The specific activity of wild type enzyme and four mutant enzymes (R170H, R218H, 
R452G and R572H, showing no loss-of-function under standard conditions) was measured 
without adding PLP to the assay, as described in Material and Methods. Specific activities are 
expressed in pmoles of ALA produced by mg protein after subtracting the specific activity of 
C344X (negative control). The statistical significance of the comparisons between each 
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mutant and the normal enzyme was established using Student-s t-test (*: p value < 0.05). Two 
mutants (R170H and R218H) display PLP sensitivity. 
B/ The specific activity of wild type enzyme and four mutant enzymes (R170H, R218H, 
R452G and R572H) was measured after preincubating for 30 or 60 minutes before the assay, 
as described in Material and Methods. The statistical significance of comparisons between 
each mutant and the normal enzyme was established using Student’s t-test (*: p value < 0.05). 
Two mutants (R170H and R218H) are thermosensitive. 
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Abstract  
X-linked Sideroblastic Anemia (XLSA) is the most common genetic form of sideroblastic 
anemia, a heterogeneous group of disorders characterized by iron deposits in the mitochondria 
of erythroid precursors. XLSA is due to mutations in the erythroid-specific 5-aminolevulinate 
synthase (ALAS2) gene. Thirteen different ALAS2 mutations were identified in 16 out of 29 
probands with sideroblastic anemia. One third of the patients were females with a highly 
skewed X-chromosome inactivation. The identification of seven novel mutations in the 
ALAS2 gene, six missense mutations, and one deletion in the proximal promoter extends the 
allelic heterogeneity of XSLA. Most of the missense mutations were predicted to be 
deleterious and ten of them, without any published functional characterization, were 
expressed in E. coli. ALAS2 activities were assayed in vitro. Five missense mutations resulted 
in decreased enzymatic activity under standard conditions, and two other mutated proteins 
had decreased activity when assayed in the absence of exogenous pyridoxal phosphate and 
increased thermosensitivity. Although most amino-acid substitutions result in a clearly 
decreased enzymatic activity in vitro, a few mutations have a more subtle effect on the protein 
that is only revealed by in vitro tests under specific conditions. 
 
 
 
Keys words 
X-linked Sideroblastic Anemia, ALAS2, heme synthesis, protoporphyrin 
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Introduction 
 
Congenital sideroblastic anemia (CSA) comprises a group of heterogeneous disorders 
characterized by decreased heme synthesis and mitochondrial iron overload with ringed 
sideroblasts in the bone marrow (For a review, see Camaschella, 2009). The most common 
genetic form of CSA, X-linked Sideroblastic Anemia (XLSA, MIM# 300751), results from 
mutations in the specific erythroid gene encoding 5-aminolevulinate synthase (ALAS2, also 
known as ALASE, MIM *301300, EC 2.3.1.37) (Fleming, 2002) localized on chromosome 
Xp11.21. ALAS is the first enzyme in the heme biosynthesis pathway and catalyzes the 
condensation of glycine and succinyl-coenzyme A into 5-aminolevulinic acid (ALA), the 
precursor of the tetrapyrroles (Gibson, et al., 1958; Shemin and Kikuchi, 1958). Pyridoxal 5’-
phosphate (PLP) is the cofactor of the enzyme. Most of the 48 reported ALAS2 mutations 
responsible for XLSA are missense mutations localized in exons 4 to 11 (Bergmann, et al.). A 
variant in the proximal promoter was first reported as a mutation in an XLSA patient (Bekri, 
et al., 2003), but this variant was subsequently found in unaffected individuals, leading to the 
conclusion that it is a low frequency polymorphism and not a causal mutation (May A., 2005). 
Most of these mutations were described at the genomic level without further characterization 
of the mutated protein either in vitro or in vivo. In some patients, reduced ALAS enzymatic 
activity has been reported in the bone marrow (Bottomley, et al., 1992; Cotter, et al., 1995; 
Cox, et al., 1994; Harigae, et al., 1999a), and in others the mutated cDNA has been expressed 
in E. coli in order to study the activity of mutated protein (Cotter, et al., 1992; Cotter, et al., 
1995; Cotter, et al., 1994; Cox, et al., 1994; Furuyama, et al., 1997; Furuyama, et al., 2006; 
Furuyama, et al., 1998; Harigae, et al., 1999a; Harigae, et al., 1999b; Prades, et al., 1995). In 
addition, in 2005, the crystallographic structure of ALAS2 from Rhodobacter capsulatus (R. 
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capsulatus) was published, making it possible to map the XLSA causing mutations (Astner, et 
al., 2005). 
Here we report a series of 29 probands with SA. Thirteen different ALAS2 mutations were 
found in 16 probands. Seven of the 13 mutations had never previously been described, 
including a 48-bp deletion in the proximal promoter region. The functional impact of the 12 
remaining missense mutations was assessed in silico using bioinformatic tools. Moreover, 
cDNAs were expressed in E. coli in order to assess the functional consequences of ten amino-
acid substitutions for six novel mutations and four previously reported but so far 
uncharacterized mutations. ALAS2 activity, enzyme thermosensitivity and pyridoxine 
responsiveness were studied. 
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Materials and Methods 
Patients 
We performed genetic analyses in 29 probands (17 males and 12 females) referred to our 
laboratory with a diagnosis of CSA based on the presence of sideroblasts in the bone marrow. 
Patients with syndromic or acquired forms of SA were excluded from this study. These 
patients originated from France, other Western European countries (Germany, Switzerland, 
Belgium) and Tunisia. Blood samples for genetic analysis were obtained from the patients or 
their parents after they had given signed informed consent in accordance with the 
requirements of the French Bioethics Committee “Agence of Biomedecine”. Hematological 
parameters had been evaluated by standard methods in the respective referring hospitals, and 
erythrocyte protoporphyrin was measured as previously described (Deacon and Elder, 2001).  
 
X-inactivation study 
Analysis of X chromosome inactivation was performed as previously described (Chollet-
Martin et al., 2007) using the androgen receptor polymorphism as a marker. 
 
Molecular analysis of the ALAS2 gene  
Genomic DNA was extracted from peripheral blood using the QIAamp DNA blood Mini Kit 
(Qiagen, CA, USA). Analysis of the ALAS2 gene (Genbank genomic: NG_008983.1, 
Genbank mRNA: NM_000032.4, Genbank protein: NP_000023.2) was performed by 
bidirectional direct sequencing. The 11 exons of ALAS2, the proximal promoter (250 bp) and 
the exon-intron junctions were amplified by PCR (Supp. Table S1). After purification of PCR 
products (PCR purification kit, Qiagen CA, USA), both strands were sequenced using a Big 
Dye Terminator Cycle Sequencing kit (Applied Biosystems, Life Technologies, Carlsbad, 
CA, USA). Sequencing products were purified (Sephadex G50, GE Healthcare, Piscataway, 
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NJ, USA), and analyzed using a 3130xl Genetic Analyzer (Applied Biosystems, Life 
Technologies, Carlsbad, CA, USA) and the Seqscape analysis software (v2.6.0) (Applied 
Biosystems, Life Technologies, Carlsbad, CA, USA). Identified mutations were confirmed on 
a second sample, when available, or by family study. Numbering of ALAS2 mutations 
followed the international guidelines (www.hgvs.org/mutnomen). For the nucleotide 
numbering, +1 corresponds to the A of the ATG translation initiation codon in the reference 
sequence of the cDNA; for the amino acid numbering position 1 corresponds to the initiating 
methionine.  
 
In silico prediction of the functional impact of ALAS2 mutations 
The Grantham score (Grantham, 1974) and six bioinformatic tools were used in silico to 
predict the impact of ALAS2 mutations on protein structure or function, as previously 
described (Kannengiesser, et al., 2009). The bioinformatic tools consisted of polyphen 
(Sunyaev, et al., 2001), SIFT (Ng and Henikoff, 2003), SNP3D (Yue, et al., 2006), 
PANTHER (Brunham, et al., 2005), UMD Predictor (Frederic, et al., 2009) and GVGD 
(Tavtigian, et al., 2006).  
To get an overall estimate of the impact of each mutation, we calculated a “prediction score” 
from the number of programs that predicted that the alteration would be deleterious 
(Grantham score >100; GVGD: C25-C65; PANTHER: highly/probably deleterious; SIFT: 
affected; polyphen: damaging; UMD predictor: pathogenic; SNP3D: deleterious). 
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Localization of amino acids in Rhodobacter capsulatus 
The localization of the mutated amino acids in the 3D structure of ALAS2 was predicted by 
sequence homology using the crystal structure of ALAS from R. capsulatus (PDB 2BWN, 
2BWO and 2BWP) and Rasmol software (Sayle and Milner-White, 1995).   
 
Expression of normal and mutant ALAS2 enzymes in E. coli 
To investigate the effect of the mutations on ALAS2 activity, mutant enzymes were expressed 
in E. coli starting from a construct with the normal cDNA (pMALc2-AE2) kindly provided by 
Dr David Bishop (Cotter, et al., 1994). pMALc2-AE2 encodes a recombinant fusion protein 
consisting of a maltose binding protein (MBP, 387 AA) linked to the N-terminus of the 
mature human ALAS2 (509AA).  We introduced the different mutations by site-directed 
mutagenesis using a Quick change kit (Stratagene, La Jolla, CA, USA) according to the 
manufacturer’s instructions. The sequences of the mutagenesis primers are available upon 
request. The coding region of the resulting cDNAs was verified by sequencing.  
Escherichia coli BL21 DE3 competent cells (Invitrogen, Life Technologies, Carlsbad, 
California, USA) were transformed with expression plasmids, and overnight cultures were 
grown in LB (Lennox L Broth Base, Invitrogen, Life Technologies, Carlsbad, California, 
USA) medium with 100 mg/ml ampicillin (PANPHARMA, Fougères - France). The next day, 
20 ml of cultures in LB/ampicillin medium were initiated with the overnight cultures and 
grown to 1.2 A600 units. ALAS2 synthesis was induced by adding 0.1 mM isopropyl b-D-
thiogalactopyranoside (IPTG) in the presence of 0.5 mM 4,6-dioxoheptanoic acid (Sigma-
Aldrich, St. Louis, MO, USA), also known as succinyl acetone, a strong inhibitor of the ALA 
dehydratase enzyme to prevent the transformation of ALA into porphyrins. Incubation was 
carried out in LB/ampicillin medium for 4 hr at 22°C. Cells were pelleted at 2500 rpm for 10 
min, and then frozen at -80°C. The assay of ALAS2 activities of the control and mutant 
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enzymes under standard conditions was performed on crude bacterial lysates as previously 
described (Lien and Beattie, 1982) with modifications. Pellets were sonicated in 300 µl of 
HEPES 50 mM pH 7.5 while maintained in ice. The total protein concentration was measured 
by means of a protein assay (Bio-Rad Laboratories GmBh, Hercules, CA, USA), and the 
samples were adjusted to a concentration of 0.2 mg of total protein/ml. Six hundred µl of 
samples were preincubated for 5 minutes at 37°C before the assay, then 100 µl of a mixture 
containing 1 mM Succinyl-CoA, 10 mM Glycine, 50 mM HEPES and 0.5 mM PLP (all from 
Sigma-Aldrich, St. Louis, MO, USA) were added to samples. The reaction was stopped by 
adding 60 µl of 100% trichloroacetic acid either immediately (T0) or after 20 minutes (T20) 
at 37°C. The reaction product 5-aminolevulinate (ALA) was quantified by colorimetry, after a 
reaction of ALA with acetyl acet ne (Fluka analytical, Sigma-Aldrich, St. Louis, MO, USA) 
(Mauzerall and Granick, 1956). The ALA pyrroles were not separated from other pyrroles 
present in the bacterial lysate before adding Erlich’s reagent. Instead, the ALA synthesized 
during the incubation was calculated from the OD obtained with Erlich’s reaction after 
subtracting a blank corresponding to the OD obtained with the lysate from a bacterial clone 
expressing the ALAS2 C344X mutant. This mutant encodes a truncated protein shown to be 
devoid of enzymatic activity by the lack of difference in OD between T0 and T20 (data not 
shown). We checked that all bacterial lysates corresponding to wild type and mutant 
recombinant ALAS2 (including the C344X mutant) yielded identical OD values at T0. 
The specific activity (SA) was expressed in pmol of ALA/mg total protein at 37°C. The 
residual activity (%) was determined by expressing the specific activity of mutants relative to 
that of the wild type ALAS2.  
In some cases, specific assay conditions were used consisting of either omitting PLP from the 
incubation mixture or preincubating the bacterial lysate at 37°C for 30 or 60 minutes instead 
of 5 minutes.  The significance of the results was estimated using Student’s t-test.   
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Immunoblotting 
2.5 µg of total protein of the supernatant from bacteria lysates were taken up onto 1X 
Laëmmli buffer, and heated for 10 minutes at 100°C. Samples were analysed by SDS-PAGE 
using an 8% polyacrylamide gel followed by electro-transfer on a polyvinylidene fluoride 
(PVDF) membrane. Loading and transfer were confirmed by Ponceau red staining. After pre-
incubation in blocking solution (7% skimmed milk in Tween 20 in Tris buffered saline, TBST 
0,15%) overnight at 4°C, the membrane was incubated with an anti-MBP antiserum (1/20 
000, E8030S, New England Biolabs, Ozyme, Ipswich, MA, USA) for 2H at room 
temperature. After washing three times with TBST for 10 minutes each time, the membrane 
was incubated with a secondary anti rabbit IgG, linked to Horseradish peroxidase (1/20 000, 
Amersham GE Healthcare, Piscataway, NJ, USA) for 2H at room temperature. The MBP 
fusion proteins were visualized (Immobilon Western, chemiluminescent HRP substrate, 
Millipore Corporation, Billerica, MA, USA) according to the Manufacturer’s instructions.  
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Results 
Twenty-nine patients with a diagnosis of CSA were referred to our laboratory for molecular 
exploration. All of them had ringed sideroblasts in the bone marrow, and most of them had 
mild to severe anemia at the time of referral. The ALAS2 gene was sequenced. Thirteen 
different mutations, including 12 substitutions and 1 deletion, were identified in 16 probands 
(10 males and 6 females). Table 1 summarizes clinical data for patients carrying an ALAS2 
mutation.  
Five of the six affected females had highly skewed X inactivation consistent with a diagnosis 
of XLSA (data not shown). The remaining affected female (proband 8) was not informative 
for the androgen receptor polymorphism.  
Six of these mutations had already been reported (Bottomley, 2004; Bottomley, et al., 1995; 
Goncalves, et al., 2004; May and Bishop, 1998), whereas the other seven had not been 
described before (Harigae and Furuyama). Twelve of these 13 mutations caused amino acid 
substitutions (Table 1), and the thirteenth was a 48-bp deletion (c.-91_-44del) in the proximal 
promoter (Table 1 and Figure 1). This deletion led to the removal of the TATA-like box 
localized between -82 and -76 bp upstream of the translational initiating codon (Cox, et al., 
1991) and of the first 9 nucleotides of exon 1. A rare P520L variant, previously reported as a 
putative modifier of iron overload with an allelic frequency of 0.0013 in Caucasians (Lee, et 
al., 2006), was found in one female proband (number 13, Table 1) in the absence of any other 
sequence variation.  
Erythrocyte protoporphyrin concentration was measured in six patients carrying an ALAS2 
mutation (Table 1). In all XLSA cases, the protoporphyrin concentration was within the 
normal range of values (less than 1.9 µmoles/L of red blood cells).  
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We used various different in silico software products to predict the functional consequences 
of the ALAS2 missense mutations. All the substitutions were predicted to be deleterious, apart 
from R218H and E242K (Supp. Table S2).  
To assess in vitro the functional consequences of ten amino acid substitutions that had not 
been studied before (ten missense mutations corresponding to six novel mutations and four 
previously reported mutations without functional data) we expressed the mutant cDNAs in 
E. coli. Immunoblotting was performed to confirm that the expression level of recombinant 
normal and mutant proteins were similar (Supp. Figure S1). When the enzymatic activity was 
assayed from E. coli lysates immediately after cell disruption, five ALAS2 mutants (E242K, 
D263N, P339L, R375C, R411H) displayed significantly reduced ALAS2 activity, with 
residual activity ranging between 14 and 65 % of the normal construct (Figure 2 and Table 2).  
Expression of the remaining five mutated cDNAs (R170H, R218H, R452G, P520L and 
R572H) resulted in the production of a protein with an enzymatic activity that was no 
different from that of the normal construct.  
For four mutants, we also measured the activity of the protein in the absence of added 
exogenous PLP (Figure 3a). R170H and R218H mutants displayed significantly reduced 
activity in this situation, whereas neither R452H nor R572H did. We also tested the thermal 
stability of these four mutated enzymes by pre-incubating them at 37°C for 30 or 60 minutes 
prior to the enzymatic assay (Figure 3b). Once again, the R170H and R218H mutants 
displayed significantly increased thermosensitivity, while the R452H and R572H mutants did 
not significantly differ from the wild type. Adding exogenous PLP to the preincubation 
medium prevented the loss of activity induced by preincubating at 37°C for all the mutants as 
well as for the normal enzyme (data not shown). 
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Discussion 
The results reported here for a series of 29 probands with CSA highlights a number of 
interesting points regarding the genetic heterogeneity of the disease and the functional 
consequences of ALAS2 mutations. ALAS2 variants were found in 16 out of the 29 probands, 
including a P520L variant previously reported as being a rare polymorphism (Lee, et al., 
2006). Recently, other gene defects have been identified in autosomal recessive forms of CSA 
(MIM #205950): a homozygous mutation was found in GLRX5 in a consanguineous proband 
(Camaschella, et al., 2007), and SLC25A38 which encodes a putative glycine transporter, was 
found to be mutated in the affected members of different families (Guernsey, et al., 2009). 
Thus for the 13 probands without any ALAS2 mutation, and for one patient with the P520L 
variant, these two genes were explored and mutations were identified in SLC25A38 for four 
probands (manuscript submitted). No variant was identified in any of the three genes explored 
in the other 9 patients; the characteristics available for these patients are reported in Suppl. 
table S3). This proportion is similar to that reported by Bergmann et al. (Bergmann, et al., 
2010), suggesting that other loci must be involved. 
Our data extend the allelic heterogeneity of XSLA, since we identified seven novel mutations 
including a deletion in the proximal promoter region, in addition to five mutations already 
known. As expected, XLSA symptomatic heterozygous females displayed highly skewed 
X-chromosome inactivation (Aivado, et al., 2006; Cazzola, et al., 2000).  
We clearly show that a defect in the first step of the heme biosynthetic pathway prevents the 
abnormal accumulation of erythrocyte protoporphyrin both in patients with ALAS2 mutations 
(Table 1) as well as in one patient with the SLC25A38 mutation (data not shown). Therefore, 
this simple measurement may provide a useful screening test before sequencing ALAS2 and 
SLC25A38. Indeed, elevated erythrocyte protoporphyrin levels have been described in other 
anemic syndromes, including many types of CSA linked to ABCB7, SLC19A2 or 
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mitochondrial defects (Camaschella, 2009). Furthermore, erythrocyte samples were available 
for three unexplained cases of CSA (without any identified mutations of ALAS2 or 
SLC25A38) out of the 14 in our series. In contrast to the XLSA patients, they had an elevated 
level of erythrocyte protoporphyrin (>1.9 µmoles/L red blood cells, data not shown).  
Finally, we addressed the functional consequences of ALAS2 mutations in order to evaluate 
their deleterious impact. The deletion in the proximal promoter of the ALAS2 gene led to the 
elimination of the TATA-like motif and the first 9 bp of exon 1. The TATA-like motif has 
been shown to be functionally important by mutagenesis studies (Surinya, et al., 1997). It is 
likely that some other sequence upstream of the deletion may act as a weak promoter, since 
ALAS2 mRNA was detected at a lower concentration in the bone marrow of the male patient 
15 than in unrelated controls (data not shown). The complete loss of ALAS2 expression is 
probably lethal, as shown by the absence of ALAS2-null embryos following specific 
disruption of ALAS2 gene in mice (Nakajima, et al., 1999).  
The finding of a previously reported variant P520L as the only sequence variation in a 
proband female with a highly skewed pattern of X-inactivation raises the question of the 
possible relevance of this mutation. However, expression studies of the P520L cDNA failed 
to reveal any functional impact. 
The functional consequence of the six novel missense mutations was evaluated by studying 
the enzymatic activity of the recombinant mutant protein expressed in E. coli. Three 
previously reported mutants, for which such data were not available, were also studied 
(Table 1). A significant decrease in the enzymatic activity measured in vitro was evidenced 
for five mutants: E242K, D263N, P339L, R375C and R411H (Table 3). The histidine 
substitution at position 411 (R411H mutation) decreased ALAS2 activity to the same extent 
as the cysteine substitution previously reported (Furuyama, et al., 1998).  
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For four other mutations (R170H, R218H, R452H, R572H), in vitro activity was not different 
from the wild type control under standard conditions. Two of these mutants (R170H and 
R218H) showed reduced activity in the absence of exogenous PLP and increased 
thermosensitivity.  This may be explained by reduced affinity for PLP and higher sensitivity 
to thermal denaturing of the apoenzyme as compared to the holoenzyme, the proportion of the 
two forms being modified by the presence of added PLP. These results are consistent with the 
structural analysis of ALAS from R. capsulatus leading to the prediction that the substitution 
of the R170 would affect the binding of PLP (Astner, et al., 2005). However, the patient with 
the R170H mutation did not respond to PLP therapy. Because in silico tools did not predict 
any deleterious impact for R218H, and because both this mutant and the R170H mutant 
behaved similarly in our functional studies, we localized the corresponding positions on the 
quaternary structure of R. capsulatus (see Supp. Figure S2). Interestingly, A75 (at a position 
homologous to that of R218 in humans) in one monomer is quite close to R28 (at homologous 
position to human R170) on the other monomer, suggesting the possibility that these two 
amino acids may be important for the dimerization of ALAS2. 
Finally, two mutated proteins, R452G and R572H, did not differ from the wild type in the in 
vitro system despite damaging in silico predictions. These two mutants were as active and as 
thermostable as the normal enzyme. Similar findings had previously been reported for other 
mutations, including R452C and R452H (Furuyama, et al., 2006). Although the R452G and 
R572H mutants did not display loss-of-function in E. coli, several lines of evidence support 
their implication in XLSA. The CGC codon encoding R452 is a hot spot for mutations. This  
arginine R452 has been found to be substituted in approximately one-quarter of patients with 
XLSA (Furuyama, et al., 2006). In our series, R452C occurred in two independent probands. 
Two independent probands were also carrier of the R572H mutation and one of them, for 
whom blood sample was available, showed an erythrocyte protoporphyrin concentration at the 
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lower end of the normal range. These observations suggest that R452G and R572H are causal 
mutations. We can hypothesize the implication of additional factors in the bone marrow or a 
defective enzyme processing as has been suggested for K299Q and D190V, previously 
reported to display normal activities (Cotter, et al., 1995; Furuyama, et al., 1997). 
As previously reported, iron overload may be a major complication of XLSA, and the iron 
depletion by either iron chelators or phlebotomy (Camaschella, 2008) not only effectively 
prevents the deleterious effects of iron overload, but also improves erythropoiesis.   
A correlation between these “milder” defects and the phenotype of the patients remains 
speculative, given the known intrafamilial variability of XSLA. It is noteworthy that the 
patient with R452G has a mild anemia, and the two patients with the R572H mutations have 
near-to-normal hemoglobin levels, microcytosis and a relatively late onset of the disease. It is 
interesting to note the wide variability in the degree of anemia in patients with ALAS2 
mutations, ranging from a baby boy with a very severe form of the disease requiring repeated 
blood transfusions (patient 3, see Table1), to patients with mild microcytosis diagnosed at age 
46 and 57 respectively (patients 14 and 15, see Table1). In these last two cases, the diagnosis 
was suspected because of iron overload in absence of transfusion, and confirmed by bone 
marrow examination revealing the presence of ringed sideroblasts.  
In conclusion, we confirm in a large cohort of patients that about half of the cases of non 
syndromic sideroblastic anemia are accounted for by ALAS2 mutations, and that a high degree 
of clinical heterogeneity parallels the diversity of the mutations and of their functional 
consequences.  
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Table 1: Hematological and biochemical parameters of patients presenting ALAS2 mutations 
ALAS2 Mutation a Patient Gender Age at 
onset 
(years) 
Pyridoxine 
Response  
Hb 
(g/dL) 
MCV 
(fL) 
Tf Sat 
(%) 
Ferritin 
(µg/L) 
PP 
(µmoles/L 
RBC) localization cDNA b Protein 
Genetic 
report 
1 F 43 - 11.2 96 100 371 n.a. exon 5 c.509G>A p.Arg170His (May and 
Bishop, 1998) 
2 F 0.5 - 8  84 100 1448 n.a. exon 6 c.653G>A p.Arg218His present study 
3 M 0.5 + 1.5 69 n.a. 256 n.a. exon 6 c.724G>A p.Glu242Lys present study 
4 F 20 + 9.2 41c 68 899 n.a. exon 6 c.787G>A p.Asp263Asn  (Bottomley, 
2004) 
5 M 31 + 3.5 76 n.a. 1172 1.40 exon 8 c.1016C>T p.Pro339Leu present study 
6 M 47 n.a. 6.3 <70 63 2537 1.70 exon 8 c.1123C>T p.Arg375Cys present study 
7 M 7 + 7.2 60 86 780 n.a. exon 9 c.1231C>T 
 
p.Arg411Cys (Bottomley, 
2004)e 
8 F d n.a. n.a. 9.1 41 c  71 600 1.80 exon 9 c.1232G>A 
 
p.Arg411His (Goncalves, et 
al., 2004) 
9 F 63 + 10.4 73 70 428 1.65 exon 9 c.1232G>A 
 
p.Arg411His (Goncalves, et 
al., 2004) 
10 M 38 + 10.4 70 93 2284 n.a. exon 9 c. 1354C>G p.Arg452Gly present study 
11 M 20 + 11.3 62 100 1172 n.a. exon 9 c.1354C>T 
 
p.Arg452Cys (Bottomley, et 
al., 1995)f 
12 M n.a. + 10 <70 n.a. 1000 0.56 exon 9 c.1354C>T 
 
p.Arg452Cys (Bottomley, et 
al., 1995)f 
13 F 45 - 8.5 56 n.a. n.a. n.a. exon 9 c.1559C>T p.Pro520Leu (Lee, et al., 
2006) 
14 M 46 - 13.2 68 63 1000 0.64 exon 11 c.1715G>A p.Arg572His present study 
15 M 57 + 12.2 73 28 1000 n.a. exon 11 c.1715G>A p.Arg572His present study 
16 M 0.75 +/- 6.3 53 n.a. 1200 n.a. Promoter c.-91_-44 del - present study 
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M: Male, F: Female, Hb: Hemoglobin; MCV: Mean Corpuscular Volume; Tf Sat: Transferrin Saturation; PP: erythrocyte protoporphyrin; RBC: 
red blood cells; n.a.: not available. 
a
 the Genbank reference sequence for ALAS2 gene are: Genbank genomic: NG_008983.1, Genbank mRNA: NM_000032.4 and Genbank protein: 
NP_000023.2. 
b
 Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference 
sequence, according to HGVS guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.  
c: values of MCV were indicated for the microcytic population of RBCs in female patients in whom two populations of RBCs were detected.  
d
 not informative for X inactivation. 
Expression data have been studied for the following mutations: e pR411C (Furuyama, et al., 1998), and f p.R452C (Furuyama, et al., 2006). 
Normal values: Hb: 12-15.5 g/dL (anemia: Females<12g/dL, Males <13g/dL), MCV: 80-90 fL (microcytosis: <80fL), Tr Sat: 12-45% (Females) 
15-50% (Males), Serum Ferritin: Females 20-150 µg/L, Males 30-300 µg/L. PP <1.9µmoles/L RBC. 
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TABLE 2: Summary of results for missense mutations 
 
Structural impacta 
 ALAS2 activity  
ALAS2  
Mutation 
AA RC Localization 
In silico 
 protein score Standard: with 
added PLP 
Specific: without 
added PLPb 
p.Arg170Hisc Arg28 
Internal  
β1-sheet 
strand 1 
Deleterious 117 % Defective 
p.Arg218His Ala75 
Internal 
α3-helix 
Neutral 83 % Defective   
p.Glu242Lys Glu99 
Surface 
α4-helix  
Neutral 17 % ‡  ND 
p.Asp263Asn Asp120 
Internal 
α5-helix 
Deleterious 14 % ‡ ND 
p.Pro339Leu Pro196 
Surface 
1aa before α8-helix  
Deleterious 65 % ‡ ND 
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p.Arg375Cys Arg232 
Surface 
α8-helix 
Deleterious 53 % ‡ ND 
p.Arg411His Arg268 Deleterious 23 % ‡ ND 
p.Arg411Cys Arg268 
Internal 
α1-helix 
Deleterious 25 % f ND 
p.Arg452Glyd Met309 Deleterious 109 % Normal 
p.Arg452Cysd Met309 
Surface 
α14-helix 
Deleterious 100 % f ND 
p.Pro520Leu Pro377 Internal Deleterious 87% ND 
p.Arg572His NDe NDe Deleterious 126 % Normal 
AA RC: amino acid, Rhodobacter capsulatus; ND: not determined; ‡ Student’s t-test, p value < 0.05 
a
 crystallography of ALAS2 from R. capsulatus permitted molecular modeling to predict the localizations of numerous mutations on the protein 
(Rasmol, PDP 2BWN, 2BWO and 2BW).  
b
 or preincubated at 37°C. 
c d
: These amino acids are hot spots of mutation with numerous substitutions: R170L/S/C (Edgar, et al., 1998; Furuyama and Sassa, 2002; May 
and Bishop, 1998) and R452H/C/S/G (Bottomley, et al., 1995) and this study. 
e
 Structural prediction for R572H is not possible because the C-terminal part of human enzyme is longer than enzyme of R. capsulatus.  
f previously described (Furuyama, et al., 2006).
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Figure Legends 
 
Figure 1: Hemizygous deletion of 48 base pairs in the proximal promoter of ALAS2 gene 
A: PCR amplification of the promoter region from a normal control (lane 1; expected size 
627 bp); male proband 15 (lane 2; shorter PCR product of 579 bp) and his mother (lane 3; 
healthy carrier); M: DNA molecular weight markers (Fermentas, 100 bp ladder); 
B: Sequence of the proximal promoter of the ALAS2 gene (Adapted from Cox, et al., 1991) 
showing the TATA-like box (in bold), the beginning of exon 1 (underlined), and the deletion 
(underlined in gray) 
 
Figure 2: Residual activities of the various different recombinant ALAS2 mutant 
enzymes assayed under standard conditions 
The residual activity of each mutant is expressed as a percentage of the normal enzyme 
activity as described in Material and Methods. Enzyme activity was measured on at least 3 
independent bacterial cultures. The statistical significance of comparisons of the specific 
activities between each mutant and the normal enzyme was established using Student’s t-test 
(*: p value < 0.05). Five mutants (E242K, D263N P339L, R375C and R411H) display 
significant loss-of-function. 
 
Figure 3: PLP-dependence and thermosensitivity of the recombinant normal and 
mutant ALAS2  
A/ The specific activity of wild type enzyme and four mutant enzymes (R170H, R218H, 
R452G and R572H, showing no loss-of-function under standard conditions) was measured 
without adding PLP to the assay, as described in Material and Methods. Specific activities are 
expressed in pmoles of ALA produced by mg protein after subtracting the specific activity of 
C344X (negative control). The statistical significance of the comparisons between each 
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mutant and the normal enzyme was established using Student-s t-test (*: p value < 0.05). Two 
mutants (R170H and R218H) display PLP sensitivity. 
B/ The specific activity of wild type enzyme and four mutant enzymes (R170H, R218H, 
R452G and R572H) was measured after preincubating for 30 or 60 minutes before the assay, 
as described in Material and Methods. The statistical significance of comparisons between 
each mutant and the normal enzyme was established using Student’s t-test (*: p value < 0.05). 
Two mutants (R170H and R218H) are thermosensitive. 
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Table 1: Hematological and biochemical parameters of patients presenting ALAS2 mutations 
ALAS2 Mutation a Patient Gender Age at 
onset 
(years) 
Pyridoxine 
Response  
Hb 
(g/dL) 
MCV 
(fL) 
Tf Sat 
(%) 
Ferritin 
(µg/L) 
PP 
(µmoles/L 
RBC) localization cDNA b Protein 
Genetic 
report 
1 F 43 - 11.2 96 100 371 n.a. exon 5 c.509G>A p.Arg170His (May and 
Bishop, 1998) 
2 F 0.5 - 8  84 100 1448 n.a. exon 6 c.653G>A p.Arg218His present study 
3 M 0.5 + 1.5 69 n.a. 256 n.a. exon 6 c.724G>A p.Glu242Lys present study 
4 F 20 + 9.2 41c 68 899 n.a. exon 6 c.787G>A p.Asp263Asn  (Bottomley, 
2004) 
5 M 31 + 3.5 76 n.a. 1172 1.40 exon 8 c.1016C>T p.Pro339Leu present study 
6 M 47 n.a. 6.3 <70 63 2537 1.70 exon 8 c.1123C>T p.Arg375Cys present study 
7 M 7 + 7.2 60 86 780 n.a. exon 9 c.1231C>T 
 
p.Arg411Cys (Bottomley, 
2004)e 
8 F d n.a. n.a. 9.1 41 c  71 600 1.80 exon 9 c.1232G>A 
 
p.Arg411His (Goncalves, et 
al., 2004) 
9 F 63 + 10.4 73 70 428 1.65 exon 9 c.1232G>A 
 
p.Arg411His (Goncalves, et 
al., 2004) 
10 M 38 + 10.4 70 93 2284 n.a. exon 9 c. 1354C>G p.Arg452Gly present study 
11 M 20 + 11.3 62 100 1172 n.a. exon 9 c.1354C>T 
 
p.Arg452Cys (Bottomley, et 
al., 1995)f 
12 M n.a. + 10 <70 n.a. 1000 0.56 exon 9 c.1354C>T 
 
p.Arg452Cys (Bottomley, et 
al., 1995)f 
13 F 45 - 8.5 56 n.a. n.a. n.a. exon 9 c.1559C>T p.Pro520Leu (Lee, et al., 
2006) 
14 M 46 - 13.2 68 63 1000 0.64 exon 11 c.1715G>A p.Arg572His present study 
15 M 57 + 12.2 73 28 1000 n.a. exon 11 c.1715G>A p.Arg572His present study 
16 M 0.75 +/- 6.3 53 n.a. 1200 n.a. Promoter c.-91_-44 del - present study 
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M: Male, F: Female, Hb: Hemoglobin; MCV: Mean Corpuscular Volume; Tf Sat: Transferrin Saturation; PP: erythrocyte protoporphyrin; RBC: 
red blood cells; n.a.: not available. 
a
 the Genbank reference sequence for ALAS2 gene are: Genbank genomic: NG_008983.1, Genbank mRNA: NM_000032.4 and Genbank protein: 
NP_000023.2. 
b
 Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference 
sequence, according to HGVS guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.  
c: values of MCV were indicated for the microcytic population of RBCs in female patients in whom two populations of RBCs were detected.  
d
 not informative for X inactivation. 
Expression data have been studied for the following mutations: e pR411C (Furuyama, et al., 1998), and f p.R452C (Furuyama, et al., 2006). 
Normal values: Hb: 12-15.5 g/dL (anemia: Females<12g/dL, Males <13g/dL), MCV: 80-90 fL (microcytosis: <80fL), Tr Sat: 12-45% (Females) 
15-50% (Males), Serum Ferritin: Females 20-150 µg/L, Males 30-300 µg/L. PP <1.9µmoles/L RBC. 
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TABLE 2: Summary of results for missense mutations 
 
Structural impacta 
 ALAS2 activity  
ALAS2  
Mutation 
AA RC Localization 
In silico 
 protein score Standard: with 
added PLP 
Specific: without 
added PLPb 
p.Arg170Hisc Arg28 
Int rnal  
β1-sheet 
strand 1 
Deleterious 117 % Defective 
p.Arg218His Ala75 
Internal 
α3-helix 
Neutral 83 % Defective   
p.Glu242Lys Glu99 
Surface 
α4-helix  
Neutral 17 % ‡  ND 
p.Asp263Asn Asp120 
Internal 
α5-helix 
Deleterious 14 % ‡ ND 
p.Pro339Leu Pro196 
Surface 
1aa before α8-helix  
Deleterious 65 % ‡ ND 
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p.Arg375Cys Arg232 
Surface 
α8-helix 
Deleterious 53 % ‡ ND 
p.Arg411His Arg268 Deleterious 23 % ‡ ND 
p.Arg411Cys Arg268 
Internal 
α1-helix 
Deleterious 25 % f ND 
p.Arg452Glyd Met309 Deleterious 109 % Normal 
p.Arg452Cysd Met309 
Surface 
α14-helix 
Deleterious 100 % f ND 
p.Pro520Leu Pro377 Internal Deleterious 87% ND 
p.Arg572His NDe NDe Deleterious 126 % Normal 
AA RC: amino acid, Rhodobacter capsulatus; ND: not determined; ‡ Student’s t-test, p value < 0.05 
a
 crystallography of ALAS2 from R. capsulatus permitted molecular modeling to predict the localizations of numerous mutations on the protein 
(Rasmol, PDP 2BWN, 2BWO and 2BW).  
b
 or preincubated at 37°C. 
c d
: These amino acids are hot spots of mutation with numerous substitutions: R170L/S/C (Edgar, et al., 1998; Furuyama and Sassa, 2002; May 
and Bishop, 1998) and R452H/C/S/G (Bottomley, et al., 1995) and this study. 
e
 Structural prediction for R572H is not possible because the C-terminal part of human enzyme is longer than enzyme of R. capsulatus.  
f previously described (Furuyama, et al., 2006)  
Page 51 of 59
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
Supp. figure S1: Immublotting  
Western blot analysis of bacterial cell lysates from E. coli transformed with normal and mutant ALAS2 cDNAs. After the transfer, the 
membranes were probed with a primary antibody directed against MBP. 
MW: reported molecular weight of the ladder (PageRulerTM prestained protein ladder, Fermentas, Thermo Fischer Scientific). 
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Suppl. figure S2: Localization of Arg28 (e.g. R170 in human) and Ala75 (e.g. R218 in human) on ALAS of Rhodobacter capsulatus. 
 
The structure of ALAS of R. capsulatus (PDB 2BWO, Rasmol software, 2 ALAS dimers) is represented. The blue ribbon and the cyan ribbon 
correspond to two monomers. Arg28 (in yellow) on one monomer and Ala75 (in red) on the other monomer are quite close to each other in the 
quaternary structure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B
C
ALA75
ARG28
ALAS
dimer
ALAS
dimer
Monomer A
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R. capsulatus
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Supp. table S1: Primers Table 
 
Exon  Sequence Amplicon 
length (bp) 
Prom -1 F TGG TCT GAT TCC AAA GCC CAA ATG 627 
 R CGA GGA AAG AGA CAA AAA GGG GGA G  
2 F TTG CCA GGC CCT CAT GAT GGA A 325 
 R AGG CAA AGA TGG CCA GTA TAA CTT GGA  
3 F GGC TTT AGG GGT ACA TTA GAT CTC AGC A 324 
 R ATC ATG GGA TGT GTA CTG GCT GCT TTT  
4 F TGT GTT GCA TTG AGC TTA AAG AGG ACA A 295 
 R AAG GCC CTT CTG TAC TGT TTC CCC TAC T  
 F GAG TTG GAG AAC TCA AAA TCA GCA ACA T 418 
 R CCC AAG TTT CCA CTG CCA GCT CT  
5  Internal sequence Primer   
 R TTC CAT GTG TGG TTT TTC ATC TCC TCT 380 
6 F GAG AAA CCT ACC CAG TTC CTC GAT GC 316 
 R ACT GGA TGC TGT ATT GCA GGA TAC CA  
7 F GGT TGA AGT GGG AGT ACT GGG ACA GA 296 
 R TGA TCA TCA TGG TTT TTG TGA GAC CAA  
8 F GAG ATG GAG CTG GGG AAG GGT TAT 280 
 R ATT TTG TAA GGG CCT CCT CTC TGG A  
9 F TGT TGC TCT GGG ACT GAT TAT GGG A 387 
 R GGA GCG TGA GGC TCC CAG AAT AA  
10 F AGC TAG TGA TGG TGG AGC CAG AGT G 282 
 R TCT TTC AGA TCC TGG GGC TGA GG  
11 F GGC TCA TCT GTA CTG TGA CAG ATT TGG A 324 
 R GGC ACA CAA CAA AGC AGA AGA CAG G  
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Supp. Table S2: in silico evaluations of 12 ALAS2 mutations 
ALAS2 
Mutation 
(protein) 
Grantham 
Score 
GVGD 
£
 PANTHER SIFT Polyphen UMD predictor SNP3D 
In silico  
Score
 $
 
p.Arg170His 29 Moderate 
risk 
C25 
Highly 
deleterious 
-4.1649 
Affected  
0.00 
probably 
damaging 
PSIC: 2.626 
Probable 
polymorphism  
59 
Deleterious 
-1.29 
Deleterious 
5/7 
p.Arg218His 29 Weak risk 
C0 
Unlikely 
deleterious 
-2.31925 
Tolerated 
0.11 
Benign 
PSIC: 0.241 
Polymorphism 
47 
Non 
deleterious 
1.44 
Neutral 
0/7 
p.Glu242Lys 56 High risk 
C55 
Unlikely 
deleterious 
-1.99823 
Tolerated 
0.44 
Benign 
PSIC: 1.163 
Polymorphism  
41 
Non 
deleterious 
1.41 
Neutral 
1/7 
p.Asp263Asn 23 Weak risk 
C15 
Probably 
deleterious 
-2.78604 
Affected 
0.00  
 
possibly 
damaging 
PSIC: 1.976 
Probable 
polymorphism  
53 
Deleterious 
-0.60 
Deleterious 
4/7 
p.Pro339Leu 98 High risk 
C65 
Highly 
deleterious 
-4.73676 
Affected 
0.00  
 
probably 
damaging 
PSIC: 3.181 
Pathogenic 
82 
Deleterious 
-2.34 
Deleterious 
6/7 
p.Arg375Cys 180 High risk 
C65 
Highly 
deleterious 
-4.79784 
Affected 
0.00  
 
probably 
damaging 
PSIC: 2.734 
Pathogenic 
100 
Deleterious 
-1.12 
Deleterious 
7/7 
p.Arg411His 29 Moderate 
risk 
C25 
 
error* 
Affected 
0.00  
 
probably 
damaging  
PSIC: 2.686   
Pathogenic 
100 
Deleterious 
-2.63 
Deleterious 
5/6 
p.Arg411Cys 180 High risk 
C65 
 
error * 
Affected 
0.00  
 
probably 
damaging 
PSIC: 3.361 
Probably 
pathogenic 
71 
Deleterious 
-3.31 
Deleterious 
6/6 
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p.Arg452Gly 125 High risk 
C65 
Possibly 
deleterious 
-2.75867 
Tolerated 
0.024 
probably 
damaging 
PSIC: 2.119 
pathogenic 
82 
Non 
Deleterious 
1.16 
Deleterious 
6/7 
p.Arg452Cys 180 High risk 
C65 
Highly 
deleterious   
-4.26738 
Affected 
0.03 
 
probably 
damaging 
PSIC: 2.174 
Pathogenic 
100 
Non 
Deleterious 
0.47 
Deleterious 
6/7 
p.Pro520Leu 98 High risk 
C65 
Highly 
deleterious 
-4.7838 
Affected 
0.01 
probably 
damaging 
PSIC: 2.899 
Pathogenic 
82 
Non 
Deleterious 
0.46 
Deleterious 
5/7 
p.Arg572His 29 Weak risk 
C0 
Unlikely 
deleterious 
-2.25602 
Affected 
0.01 
probably 
damaging 
PSIC: 2.103 
Pathogenic  
76 
error Deleterious 
3/6 
* failure of the software to give a prediction 
£  For GVGD we used the ALAS2 sequences for Homo sapiens (isoform 1), Mus musculus, Rattus norvegicus, Bos taurus and Danio rerio.  
$  To get an overall impression of the likely impact of each mutation, we calculated a “prediction score” from the number of programs that 
predicted that the alteration would be deleterious (Grantham score >100; GVGD: C25-C65; PANTHER: highly/probably deleterious; SIFT: 
affected; polyphen: damaging; UMD predictor: pathogenous; SNP3D: deleterious). 
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Supp. table S3: Proposed grouping of Congenital Sideroblastic Anemia patients  
 
 
 
$ d: day; m: month; y: years   
£ Classication of anemia: Mild, Hb >10 g/dl; moderate, Hb 7–10 g/dl; severe Hb <7 g/dl; NA: not available 
* Familial case (another brother affected) 
 
Congenital Sideroblastic 
Anemia form (Gene) 
No. of 
mutations 
No. of 
probands 
Females / 
Males 
Range of ages at 
diagnosis $ 
Characteristics 
of anemia 
(MCV) 
Severity of Anemia 
£
 
(Lowest Hb) 
X-linked sideroblastic 
anemia (ALAS2) 
13 16 6/10 6m-63y Microcytic in 
most cases 
Mild to severe 
Autosomal recessive 
(SLC25A38) 
4 4 2/2 2d-3y microcytic Severe 
- 2 0/2 3m-7m Microcytic Severe 
- 6 4/2 early-62y Non microcytic Mild (2) Severe (3) NA (1) 
 
Unexplained CSA 
- 1* 0/1 NA NA NA 
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